# US 2025/0154274 A1 · Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154274 A1
- Document ID: US20250154274A1
- Status: Published application
- Kind: A1
- Application number: 19/025,631
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2015-12-17
- Assignees: Bristol-Myers Squibb Company; Celldex Therapeutics, Inc.
- Applicants: Bristol-Myers Squibb Company; Celldex Therapeutics, Inc.
- Inventors: Vladimir CORIC; Tibor KELER; Thomas DAVIS
- Web page: https://patentgrep.com/patent/US20250154274A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001129: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 39/00115: {Apoptosis related proteins, e.g. survivin or livin}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/3023: {Lung}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3053: {Skin, nerves, brain}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

## Claims

### Claim 1

A method for treating a subject afflicted with a tumor comprising administering the subject in need thereof
an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (“anti-PD-1 antibody or antigen-binding portion thereof”) in combination with
an antibody or an antigen-binding portion thereof that specifically binds to CD27 (“anti-CD27 antibody or antigen-binding portion thereof”).

### Claim 2 (depends on 1)

The method of claim 1, wherein the tumor is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the lung cancer is non-small cell lung cancer (NSCLC).

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding portion thereof cross-competes with nivolumab for binding to human PD-1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-CD27 antibody or antigen-binding portion thereof cross-competes with varlilumab for binding to human CD27.

### Claim 6 (depends on 1)

The method of claim 1, wherein:
(i) the anti-PD-1 antibody is nivolumab;
(ii) the anti-CD27 antibody is varlilumab; or
(iii) the anti-PD-1 antibody is nivolumab and the anti-CD27 antibody is varlilumab.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose ranging from at least about 0.1 mg/kg to at least about 10.0 mg/kg body weight once about every 1, 2 or 3 weeks.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of at least about 3 mg/kg body weight once about every 2 weeks.

### Claim 9 (depends on 1)

The method of claim 1, wherein the anti-CD27 antibody or antigen-binding portion thereof is administered at a dose ranging from at least about 0.01 mg/kg to at least about 10 mg/kg body weight once about every 1, 2 or 3 weeks.

### Claim 10 (depends on 9)

The method of claim 9, wherein the anti-CD27 antibody or antigen-binding fragment thereof is administered at a dose of 0.1 mg/kg body weight, 1 mg/kg body weight, or 10 mg/kg body weight once about every 2 weeks.

### Claim 11 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof and the anti-CD27 antibody or antigen-binding fragment thereof are formulated for intravenous administration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof and the anti-CD27 antibody or antigen-binding fragment thereof are administered sequentially, concurrently in separate compositions, or concurrently as a single composition.

### Claim 13 (depends on 1)

The method of claim 1, wherein:
(i) the anti-PD-1 antibody or antigen-binding portion thereof is administered at a subtherapeutic dose;
(ii) the anti-CD27 antibody or antigen-binding portion thereof is administered at a subtherapeutic dose; or
(iii) the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CD27 antibody or antigen-binding portion thereof are each administered at a subtherapeutic dose.

### Claim 14 (depends on 1)

The method of claim 1, wherein the tumor is colon cancer.

### Claim 15 (depends on 14)

The method of claim 14, further comprising determining the microsatellite status of the subject's tumor.

### Claim 16 (depends on 14)

The method of claim 14, wherein the subject has a microsatellite instability low (MSI-L) tumor or a microsatellite stable (MSS) tumor.

### Claim 17 (depends on 15)

The method of claim 15, wherein the microsatellite status of the subject's tumor is determined prior to treatment with the anti-PD-1 antibody or antigen-binding portion thereof in combination with the anti-CD27 antibody or antigen-binding portion thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the tumor is PD-L1 positive.

### Claim 19 (depends on 1)

The method of claim 1, further comprising measuring PD-L1 expression in the tumor.

### Claim 20 (depends on 1)

The method of claim 1, further comprising administering an anti-cancer agent.
